AZD-2207
AZD-2207 is a cannabinoid receptor CB1 antagonist, known for its high lipophilicity. AZD-2207 has good intestinal permeability in the Caco-2 model and can be used in research related to type 2 diabetes and obesity[1].
Product Specifications
CAS Number
866598-45-0
UNSPSC
12352005
Target
Cannabinoid Receptor
Related Pathways
GPCR/G Protein; Neuronal Signaling
Field of Research
Metabolic Disease
Smiles
O=C(C1=C(C)N(C2=CC=C(C=C2)OS(=O)(CCC(F)(F)F)=O)C(C3=C(Cl)C=C(Cl)C=C3)=N1)NN4CCCCC4
Molecular Formula
C25H25Cl2F3N4O4S
Molecular Weight
605.46
References & Citations
[1]Christer Tannergren, et al. Biopharmaceutic Profiling of Salts to Improve Absorption of Poorly Soluble Basic Drugs. J Pharm Sci. 2016 Nov;105 (11) :3314-3323.|[2]Jin Hee Kim, et al. Rengyolone inhibits inducible nitric oxide synthase expression and nitric oxide production by down-regulation of NF-kappaB and p38 MAP kinase activity in LPS-stimulated RAW 264.7 cells. Biochem Pharmacol. 2006 Apr 14;71 (8) :1198-205.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CB1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6400040-02 5x 0.1 mL
CLDN9 (Claudin 9, Claudin-9) (MaxLight 750)
Sign In for Pricing
View Details 
032486-ML750 100 µL
Beclin 1, phosphorylated (S64) (BECN1, GT197, Beclin-1, Coiled-coil myosin-like BCL2-interacting protein, Protein GT197) (MaxLight 750) discontinued
Sign In for Pricing
View Details